Background-Genome-wide association studies (GWAS) have identified loci associated with ischemic stroke (IS) and cardiovascular disease (CVD) in European-descent individuals, but their replication in different populations has been largely unexplored. Methods and Results-Nine single nucleotide polymorphisms (SNPs) selected from GWAS and meta-analyses of stroke, and 86 SNPs previously associated with myocardial infarction and CVD risk factors, including blood lipids (high density lipoprotein [HDL], low density lipoprotein [LDL], and triglycerides), type 2 diabetes, and body mass index (BMI), were investigated for associations with incident IS in European Americans (EA) Nϭ26 276, African-Americans (AA) Nϭ8970, and American Indians (AI) Nϭ3570 from the Population Architecture using Genomics and Epidemiology Study. Ancestry-specific fixed effects meta-analysis with inverse variance weighting was used to combine study-specific log hazard ratios from Cox proportional hazards models. Two of 9 stroke SNPs (rs783396 and rs1804689) were associated with increased IS hazard in AA; none were significant in this large EA cohort. Of 73 CVD risk factor SNPs tested in EA, 2 (HDL and triglycerides SNPs) were associated with IS. In AA, SNPs associated with LDL, HDL, and BMI were significantly associated with IS (3 of 86 SNPs tested). Out of 58 SNPs tested in AI, 1 LDL SNP was significantly associated with IS. Conclusions-Our analyses showing lack of replication in spite of reasonable power for many stroke SNPs and differing results by ancestry highlight the need to follow up on GWAS findings and conduct genetic association studies in diverse populations. We found modest IS associations with BMI and lipids SNPs, though these findings require confirmation.
F amily studies suggest that stroke has a substantial genetic component. 1, 2 To date, a small number of genetic variants associated with stroke have been identified in genome-wide association studies (GWAS). These studies were conducted in largely European-descent populations, though the burden of stroke is higher in minority populations in the United States. 3 Stroke incidence and mortality in African-Americans and stroke incidence in American Indians are nearly twice that of European-Americans. 4 
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Stroke is a heterogeneous disease consisting of several distinct subtypes, each having their own etiologies. 5 Ischemic stroke, the most common subtype accounting for Ϸ87% of strokes, 6 shares many risk factors with cardiovascular disease due to a common etiologic factor, atherosclerosis. 7 Shared risk factors for these diseases also may encompass genetic factors, such as gene variants involved in atherosclerosis. We sought to replicate associations between incident ischemic stroke and ischemic stroke single nucleotide polymorphisms (SNPs) identified in previous genome-wide association (GWA) or metaanalysis studies of European populations in a large sample of European-Americans (EA), and investigated whether associations were consistent for African-Americans (AA). Furthermore, we tested whether SNPs associated with myocardial infarction (MI) and cardiovascular disease risk factors (blood lipids, type 2 diabetes [T2D], and body mass index [BMI] ) also are associated with the incident ischemic stroke hazard in EA, AA, and American Indians (AI) from the Population Architecture using Genomics and Epidemiology (PAGE) 8 Study.
Methods
As part of the PAGE Study, 4 cohort studies with adjudicated stroke data were included in these analyses: Atherosclerosis Risk in Communities (ARIC), 9 Cardiovascular Health Study (CHS), 10 Strong Heart Study (SHS), 11 and Women's Health Initiative (WHI). 12 Participants were censored at the first incident ischemic stroke event, and individuals with a history of stroke or transient ischemic attack at baseline were excluded. All studies were approved by local institutional review boards, and all participants gave informed consent. The study populations are briefly described in Table 1 and below.
The WHI recruited 161 838 postmenopausal women aged 50 to 79 years old from 40 clinical centers in the United States between 1993 and 1998. 12, 13 WHI consists of an observational study, 2 clinical trials of postmenopausal hormone therapy (estrogen alone or estrogen plus progestin), a calcium and vitamin D supplement trial, and a dietary modification trial. A subset of the WHI cohort, nϭ21 000, were selected for PAGE genotyping and for inclusion in these analyses. Women were selected based on self-reported history of disease, incident event outcomes, DNA availability and consent, and racial/ethnic diversity. In the association analyses, inverseprobability weighting was used to account for this nonrandom sampling. Sample weights ranged from 1 to 60.4. DNA was extracted from blood samples collected at baseline. Incident stroke events were identified by semiannual questionnaires and adjudicated following medical record review.
The ARIC Study is a biracial population-based cohort recruited from 4 United States communities: Forsyth County, North Carolina, Jackson, Mississippi, suburban areas of Minneapolis, Minnesota, and Washington County, Maryland. 9 The 15 792 men and women in ARIC, including 11 478 non-Hispanic white participants, were between 45 to 64 years of age at baseline and were followed up for possible stroke events (http://www.cscc.unc.edu/aric/) through annual phone interviews, follow-up examinations, community hospital surveillance, and death certificates. Reported hospitalizations led to screening and, if suitable, to medical record abstraction. Potential stroke events were selected for medical records abstraction if the discharge diagnosis included a cerebrovascular disease code (International Classification of Diseases, 9th Revision, codes 430 -438), if a cerebrovascular procedure was mentioned in the discharge summary, or if the computed tomography or magnetic resonance imaging report showed evidence of acute cerebrovascular disease. 14 All suspected events were classified by computer algorithm and also by an expert physician reviewer, blinded to the automated results. A second physician reviewer adjudicated disagreements between the computer and the initial reviewer.
The CHS is a population-based longitudinal study of risk factors for cardiovascular disease in adults 65 years of age or older. 15 A total of 5201 predominantly European-Americans were recruited in 1989 to 1990 from random samples of Medicare eligibility lists at 4 field centers (Forsyth County, North Carolina, Sacramento County, California, Washington County, Maryland, and Pittsburgh, Pennsylvania), followed by an additional 687 African-Americans recruited in 1992 to 1993 (total nϭ5888). CHS participants completed standardized clinical examinations and questionnaires at study enrollment and at up to 9 annual follow-up visits, and are being followed for clinical events. Incident strokes were identified at semiannual examinations and through community surveillance, and adjudicated by neurologists. 10 Funded by the National Heart, Lung, and Blood Institute, the SHS is a population-based longitudinal study of 4549 American Indian men and women recruited from 13 communities and from centers located in 3 United States geographic areas (http://strongheart.ouhsc. edu/). SHS participants aged 45 to 74 years underwent a baseline (1989 -1991) and then 2 follow-up (1993-1995 and 1996 -1999) examinations. Incident ischemic stroke events were identified at yearly interviews or examinations and adjudicated by neurologists. Single nucleotide polymorphisms were identified using the National Human Genome Research Institute's Catalog of Published GWAS, 16 a comprehensive database of GWA investigations. GWAS SNPs and well-replicated SNPs from meta-analyses associated with stroke (nϭ9), myocardial infarction/coronary heart disease (CHD; nϭ16), T2D (nϭ19), high density lipoprotein cholesterol (HDL; nϭ17), low density lipoprotein cholesterol (LDL; nϭ16), triglycerides (nϭ4), and BMI (nϭ14) for a maximum total of 86 SNPs as of January 1, 2009, were genotyped by each study in PAGE (Table 2;  see online-only Data Supplement Tables I-III for lists of included  SNPs) . [17] [18] [19] [20] PAGE quality control measures called for exclusion of SNPs with call rates Ͻ95% or with Ͻ98% concordance among duplicate samples, and exclusion of individuals with call rates Ͻ95%, though WHI used more stringent criteria. For SNPs in ancestry-specific Hardy Weinberg disequilibrium (PϽ5x10 Ϫ5 ), intensity plot clustering was reviewed manually and SNPs were excluded if clustering was judged to be poor. SNPs that were genotyped successfully, passed quality control measures, and were available in at least 2 PAGE studies are included in the EA and AA analysis. For the AI analysis, all cardiovascular disease (CVD) risk factor SNPs passing quality control in SHS were tested; however, the 9 stroke SNPs were not genotyped.
Genotype data were coded assuming additive genetic models, with each SNP coded as a count of the variant alleles (0, 1, or 2), unless otherwise specified. Ancestry-stratified Cox proportional hazards models were minimally adjusted for age, sex, and study site (as appropriate in each substudy). African-American models additionally were adjusted for global ancestry to account for population substructure in WHI and ARIC; in CHS, study site was used as a proxy for ancestry. In SHS, AI models were adjusted for selfreported AI ancestry obtained by questionnaire. Study-specific results (or in the case of SHS, site-specific results) were combined in a fixed effects meta-analysis with inverse variance weighting using METAL software. 21 Per allele hazard ratios and 95% CI from the meta-analysis are reported. Heterogeneity for the SNP effects across PAGE cohorts was assessed using I 2 and the Q-test statistic. 22 Aggregate data from the meta-analysis and individual tests of association from each PAGE study will be made available via the database of Genotypes and Phenotypes (dbGaP). 23 Results are presented unadjusted for multiple testing, with interpretation of the multiple testing implications in the discussion. Power calculations were performed using Quanto, 24 assuming unrelated participants, population risk of ischemic stroke equaling 0.04, additive genetic models (or dominant or recessive models as appropriate based on prior reports), unmatched case control study design, effect size equal to the 95% CI closest to the null based on prior reports in European-descent populations, and the average ancestry-specific allele frequencies and number of incident ischemic stroke cases listed in Table 1 . Power estimates for GWAS-identified stroke SNPs also were corrected for "winner's curse" 25 bias using the above assumptions, with the exception of the effect size, which was based on bias-reduced estimates obtained using the method detailed in Zhong and Prentice. 26 The "winner's curse" refers to the ascertainment bias affecting gene association results; genetic associations that are significant in the initial study (GWAS) may be overestimated, while other associations (potentially underestimated) are less likely to be published and selected for follow-up. Because the "winner's curse" results are inflated, they can be difficult to replicate in follow-up studies, and if used for power calculations, can result in inflated power estimates. Zhong and Prentice 26 propose a method using conditional maximum likelihood estimation and quartile-based confidence interval procedures to estimate bias-corrected betas and selection-adjusted confidence intervals. We contrast power calculations using these bias-adjusted estimates with calculations using the original GWAS estimates.
Results
During follow-up, there were a total of 3239 incident ischemic strokes in EA, 655 in AA, and 163 in AI. A total of 9 stroke SNPs were investigated for their associations with ischemic stroke in EA and AA (genotypes were unavailable in AI). None of these SNPs was significantly associated with †Locus information based on genome build GRCh37/hg19. ‡Percent power estimates shown using reported GWAS estimate and correcting for winner's curse (in parentheses). §Alleles column lists the coded allele/other allele. Risk alleles identified in the original study are underlined. ¶Meta-analysis included ARIC and WHI, but not CHS because the stroke association for this SNP was originally reported in the CHS population.
risk of incident ischemic stroke in EA ( Table 2 ). In AA, 2 SNPs rs783396 and rs1804689) were associated significantly with ischemic stroke at PϽ0.05. The original reports for 3 of the 9 stroke SNPs described associations using dominant and recessive models rather than additive models; when we modeled SNPs similarly, results from the meta-analyses in AA and EA changed only slightly and remained nonsignificant (data not shown). In sensitivity analyses, using a smaller subset of the WHI EA women (nϭ1205) having more detailed stroke subtype information, we tested for stroke SNP associations with large artery (nϭ189), cardioembolic (nϭ531), and lacunar strokes (nϭ485). Rs10486776 was associated significantly with large artery ischemic stroke, Pϭ0.005, and rs7506045 was associated significantly with cardioembolic ischemic stroke, Pϭ0.027; no other significant associations with ischemic stroke subtypes were found. In EA, a total of 73 CVD risk factor SNPs were investigated (see online-only Data Supplement Table I ); of these, the HDL SNP rs2156552 (Pϭ0.006) and the triglycerides SNP rs2954029 (Pϭ0.048) were associated significantly with ischemic stroke (Table 3) . In AA, we tested a total of 86 CVD risk factor SNPs (see online-only Data Supplement Table II) ; 3 SNPs were associated with ischemic stroke, the HDL SNP rs1800961 (Pϭ0.0006), the LDL SNP rs6544713 (Pϭ0.022), and the BMI SNP rs11084753 (Pϭ0.024; Table 3 ). In American Indians, a smaller subset of 58 CVD risk factor SNPs were tested (see online-only Data Supplement Table  III) . Rs754523, a SNP previously associated with LDL levels, was associated with ischemic stroke, Pϭ0.0026 (Table 3) .
Discussion
In this analysis of multi-ethnic populations from 4 large cohort studies, we followed up on previous gene association study findings for ischemic stroke in diverse ancestral groups and explored whether GWAS SNPs for CVD risk factors also are associated with ischemic stroke. While several SNPs have been associated previously with ischemic stroke, including exonic variants in the MTHFR, AIM1, and F5 genes, we were unable to replicate these associations in our large EA population. Interestingly, 2 SNPs were associated significantly with incident ischemic stroke in AA, rs783396, and rs1804689. Located in an exon of the absent in melanoma-1 (AIM1) gene, whose expression is associated with melanoma tumor suppression, rs783396-A (Ala-ϾGlu) is a nonsynonymous variant. The variant was previously associated with an increased risk of ischemic stroke in EA, 19 with an odds ratio equal to 5.79 (95% CI, 2.66 -12.59), which is consistent with our finding of an increased risk of stroke in AA. However, it is possible that the original estimate was inflated due to ascertainment bias, termed the winner's curse. 25 Indeed, adjustment for winner's curse bias greatly attenuated the original estimates as well as our hypothetical power to replicate them. Rs1804689 (A allele) in the 5Ј untranslated region of the HPS1 gene was associated previously with an increased risk of ischemic stroke in CHS EA, 20 but in our AA population (ARIC and WHI) it was associated with a significantly reduced risk of ischemic stroke. Different patterns of linkage disequilibrium in this gene region potentially could explain these contradictory findings; accordingly, the average allele frequencies for the PAGE AA (0.14) and EA (0.31) are markedly different.
Because the ischemic stroke subtype may be heterogeneous in its etiology and thus have different risk factors, 27 we explored ischemic stroke subtypes in a smaller subset of WHI women having more detailed data in sensitivity analyses. We identified 2 SNPs associated with large artery and cardioembolic stroke in EA, though interestingly, these SNPs were not associated strongly with either ischemic stroke subtype in the original GWAS. 19 One important difference is that our analyses were conducted in EA women only, while the GWAS included both sexes. However, both subtype analyses have small sample sizes that may be more susceptible to spurious results.
Given our lack of replication along with our high power to replicate the lower confidence limit of previously reported or bias-adjusted effect sizes for almost half of the stroke SNPs in EA, we could suggest that previous findings may reflect type 1 error. Indeed, several others have commented on the lack of reproducibility of stroke-gene associations, 28 -30 citing low power, study design issues, population stratification, and study heterogeneity as potential causes. Several of the previous stroke studies were conducted in the case control setting and may be prone to potential selection and survival biases, in contrast to our analyses that were conducted in cohorts with many years of longitudinal follow-up and that also included some fatal stroke cases. Yet, these explanations do not appear to account for the differences in population-specific findings in our analysis. A potential explanation for the differences in population-specific results is gene-environment interaction. It might be that these SNPs exert their effects most strongly in the presence of environmental or host risk factors, which may differ between studies or between ancestry groups in the same study. Comparison of the prevalence of stroke risk factors reveals that BMI tends to be higher and T2D is more common in PAGE AA and AI than EA; hypertension is also much more common in AA than in the other groups. However, we saw the most suggestive findings for the lipids SNPs; the use of lipid lowering medications at baseline and during early follow-up was low in all groups because recruitment for each of the studies primarily occurred before the introduction and widespread use of the recent generation of lipid-lowering medications.
Although ischemic stroke and MI/CHD share many risk factors, SNPs associated with MI/CHD traits were not significantly associated with incident ischemic stroke in our population. The 9p21 locus has been associated previously with coronary heart disease 31 and myocardial infarction 32 in multiple GWAS, although findings for stroke outcomes have been mixed. A recent study 33 attributes these mixed results to stroke subtype heterogeneity and reported that the 9p21 locus was significantly associated with large artery ischemic stroke, which is consistent with prior associations for atherosclerotic disease of the coronary arteries and abdominal aorta. 32, 34 Chromosome 9p21 variants, rs10757278, rs1333049, rs2383206, rs2383207, and rs4977574 were included among the MI/CHD 9p21 SNPs we tested, but in sensitivity analyses of ischemic stroke subtypes, none were associated significantly with large artery (Pϭ0.47-0.61) or cardioembolic (Pϭ0.06 -0.24) stroke in WHI EA. However, all of these 9p21 variants were associated modestly with small vessel (lacunar) ischemic stroke (Pϭ0.04 -0.07) in EA. While inconsistent with the previous report, this finding is exploratory and was conducted in a small sample of postmenopausal women.
Overall, few CVD risk factor SNPs, including other 9p21 variants, were associated with risk of ischemic stroke in our study, with the exception of 5 lipid SNPs and 1 BMI SNP. In AA, an LDL SNP (rs6544713) and an HDL SNP (rs1800961) were associated significantly with ischemic stroke. The LDL SNP also was associated with increased LDL concentrations in all 3 ancestral groups in PAGE, while the HDL SNP, a nonsynonymous variant in the hepatocyte nuclear factor 4 alpha gene, was associated with lower HDL levels in EA and AI, and showed a similar trend in AA that was not significant. 35 These findings suggesting SNP-related lipid level differences are consistent with the increased risk of stroke that we find in our analysis, that is, SNPs associated with adverse lipid concentration trends are associated with increased risk of stroke. Similarly, in AI, the APOB SNP rs754523-T was associated with a reduced risk of stroke; this SNP also has been associated with reduced LDL levels in the PAGE study. 35 EA findings include rs2156522, which was significantly associated with ischemic stroke; this SNP has been associated previously with HDL concentrations in PAGE EA, but not in PAGE AA. 35 Conversely, the triglycerides SNP rs2954029 was associated significantly with an increased risk of stroke in EA, but slightly reduced triglyceride levels, which is contrary to what we might expect. And finally, the BMI SNP rs11084753 was associated with ischemic stroke in AA, but was not significantly associated with BMI in any of the PAGE race/ethnicity groups (Fesinmeyer MD et al, manuscript submitted to Obesity, 2011). These lipid and BMI SNP findings generally were not consistent between ancestral groups. In part, these differences may be explained by different linkage disequilibrium patterns across the loci in the different population groups. This scenario would be expected if the originally identified SNPs act as tags for the functional variant, and the tags do not extend across race/ethnicity groups due to differences in linkage disequilibrium. Indeed, the majority of SNPs identified in GWAS are noncoding, located in intergenic or intronic regions, 16 although our nonsynonymous HDL SNP (rs1800961) is a notable exception. This SNP is also interesting because it is in a gene, hepatocyte nuclear factor 4 alpha (HNF4A), with potential pleiotropic effects. HNF4A variants have been associated with lower HDL levels, as well as with Type 2 diabetes and with levels of the coagulation factor, Factor VII, suggesting that this gene is involved in multiple pathways relevant to the stroke outcome.
Potential limitations of this study include study heterogeneity, lack of detailed ischemic stroke subtype information on the entire population, and reduced power to detect modest effect sizes in the smaller American Indian population and for a number of SNPs in EA and AA. Our analysis of CVD risk factor SNPs was exploratory, and with the exception of the HDL SNP rs1800961 in AA, our findings were not statistically significant after Bonferroni correction for multiple testing and thus should be interpreted cautiously until confirmed. We tested for study heterogeneity in the meta-analysis and also assessed the magnitude of heterogeneity using I 2 , but these tests may be less robust when small numbers of substudies are analyzed, 36 such as in our case. The significant SNPs we report did not show significant evidence of study heterogeneity; but it is possible that heterogeneity may have reduced our power to detect significant associations for other SNPs. In general, allele frequencies were consistent between the different studies for the EA and AA populations, though more heterogeneity was seen for the AI, likely due to differing levels of admixture at the different regional sites in SHS. Additionally, we report power estimates adjusted for the "winner's curse" bias, which tend to be more conservative than the naïve power estimates. Effect estimates (and power) for several SNPs dropped substantially when accounting for this bias, suggesting that replication of these GWAS SNPs will be difficult in even large populations such as the PAGE EA, with more than 3200 ischemic strokes.
In spite of these limitations, our study includes large numbers of ancestrally diverse individuals with adjudicated ischemic stroke outcomes, standardized methods, and long follow-up. Much of our sample is population-based and not subject to biases that might be present in hospital-based case control studies of stroke.
Conclusions
As fine-mapping and resequencing studies begin to investigate GWAS findings in more detail, data regarding GWAS SNP replication in independent samples and across different ancestry/ethnicity groups will be increasingly important for use in prioritizing SNPs for follow-up 37 and for enhancing our understanding of population differences in common diseases. Our study contributes information about the reproducibility and magnitude of prior GWAS-identified SNPs for ischemic stroke. While none replicated in our EA PAGE population, 2 associations did generalize to AA. Furthermore, in analyses investigating CVD pleiotropy for largely GWASbased SNPs, we identified additional CVD risk factor SNPs that also may be associated with stroke in diverse United States ancestral/ethnic groups, including AA and AI, who are at high risk of this common disease. participants of the ARIC study for their important contributions.
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